

Title (en)  
SUBCUTANEOUS ANTI-HLA-DR MONOCLONAL ANTIBODY FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

Title (de)  
SUBKUTANER MONOKLONALER ANTI-HLA-DR-ANTIKÖRPER ZUR BEHANDLUNG HÄMATOLOGISCHER MALIGNITÄTEN

Title (fr)  
ANTICORPS MONOCLONAL ANTI-HLA-DR À ADMINISTRER PAR VOIE SOUS-CUTANÉE POUR LE TRAITEMENT DE TUMEURS MALIGNES HÉMATOLOGIQUES

Publication  
**EP 3337508 A4 20190403 (EN)**

Application  
**EP 16839842 A 20160818**

Priority

- US 201562208128 P 20150821
- US 201514876200 A 20151006
- US 201562262692 P 20151203
- US 2016047483 W 20160818

Abstract (en)  
[origin: WO2017034906A1] The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.

IPC 8 full level  
**A61K 39/395** (2006.01); **A61K 51/10** (2006.01); **C07K 16/28** (2006.01); **C07K 16/30** (2006.01); **C07K 16/46** (2006.01)

CPC (source: EP)  
**A61K 39/39591** (2013.01); **A61K 47/6867** (2017.08); **C07K 16/2803** (2013.01); **C07K 16/2833** (2013.01); **C07K 16/2887** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/507** (2013.01); **A61K 2039/54** (2013.01); **A61K 2039/545** (2013.01); **A61K 2039/55** (2013.01); **A61K 2039/552** (2013.01); **C07K 16/4283** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/33** (2013.01); **C07K 2317/52** (2013.01); **C07K 2317/53** (2013.01); **C07K 2317/73** (2013.01); **C07K 2317/75** (2013.01)

Citation (search report)

- [I] WO 2012151199 A1 20121108 - IMMUNOMEDICS INC [US], et al
- [XI] ANONYMOUS: "Archive History for NCT01728207: Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL.", 11 March 2015 (2015-03-11), XP055560263, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT01728207?V\_4=View#StudyPageTop> [retrieved on 20190221]
- [AD] THOMAS S. LIN ET AL: "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia", LEUKEMIA AND LYMPHOMA., vol. 50, no. 12, 19 December 2009 (2009-12-19), US, pages 1958 - 1963, XP055415743, ISSN: 1042-8194, DOI: 10.3109/10428190903186486
- [A] HOYER B F ET AL: "Biologics therapy for systemic lupus erythematosus", ZEITSCHRIFT FÜR RHEUMATOLOGIE, SPRINGER, DE, vol. 74, no. 3, 9 April 2015 (2015-04-09), pages 206 - 214, XP035478732, ISSN: 0340-1855, [retrieved on 20150409], DOI: 10.1007/S00393-014-1458-0
- [A] ZIV ROSMAN ET AL: "Biologic therapy for autoimmune diseases: an update", BMC MEDICINE, vol. 11, no. 1, 1 December 2013 (2013-12-01), XP055560340, DOI: 10.1186/1741-7015-11-88
- [XP] DEBORAH M STEPHENS ET AL: "Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies | Blood Journal", BLOOD, 3 December 2015 (2015-12-03), XP055559444, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/126/23/2740?sso-checked=true> [retrieved on 20190220]
- [XP] THOMAS M CARDILLO ET AL: "Abstract 587: Superior anti-tumor effects of an anti-HLA-DR IgG4 antibody, IMMU-114, in chronic and acute lymphocytic leukemia (CLL and ALL): Comparison to anti-CD20 therapy, chemotherapy, or combined with kinase inhibitors", CANCER RESEARCH, 1 July 2016 (2016-07-01), XP055560255, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/76/14\_Supplement/587> [retrieved on 20190221]

Citation (examination)

- SCHWEIGHOFER CARMEN D. ET AL: "Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 61, no. 12, 23 October 2012 (2012-10-23), Berlin/Heidelberg, pages 2367 - 2373, XP093104290, ISSN: 0340-7004, Retrieved from the Internet <URL:http://link.springer.com/article/10.1007/s00262-012-1362-x/fulltext.html> DOI: 10.1007/s00262-012-1362-x
- C. JACKISCH ET AL: "Subcutaneous Administration of Monoclonal Antibodies in Oncology", GEBURTSHILFE UND FRAUENHEILKUNDE, vol. 74, no. 04, 28 April 2014 (2014-04-28), DE, pages 343 - 349, XP055573377, ISSN: 0016-5751, DOI: 10.1055/s-0034-1368173
- See also references of WO 2017034906A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2017034906 A1 20170302; WO 2017034906 A8 20171012; CA 2987644 A1 20170302; EP 3337508 A1 20180627; EP 3337508 A4 20190403**

DOCDB simple family (application)  
**US 2016047483 W 20160818; CA 2987644 A 20160818; EP 16839842 A 20160818**